Icecure Medical Ltd Ord (ICCM) Stock Price, Quote & News

Company Profile

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic...

Industry: Medical Devices

Sector: Healthcare

Phone: 972 4 623 0333

Fax: 972 4 623 0222

Website: www.icecure-medical.com

Address:

7 Ha’Eshel Street, PO Box 3163, Caesarea, Israel

Seti09 Oct. 5 at 1:16 AM

$ICCM I Expect off-label to go parabolic.

1 · Reply

Seti09 Oct. 5 at 1:11 AM

$ICCM The FDA granted IceCure Medical (ICCM) marketing authorization for ProSense in women aged 70 and above. Crucially, the Right to Try Act—as codified federal law—takes legal precedence over this approved indication, allowing patients outside this demographic to access the device. This legal framework is anticipated to significantly increase patient demand for ProSense as an initial therapeutic choice. BUY, BUY, BUY. It may be in double digits sooner than you think. This is a no brainer. If it's safe for 70+ year olds, it's even safer for the 40 year old.

1 · Reply

Seti09 Oct. 4 at 10:00 PM

$GIPR $IMG $ICCM Everything, try DVLT.

0 · Reply

DreyOfAllTrades Oct. 4 at 8:50 PM

$ICCM This could be a good buy monday. Volume and AH was looking pretty nice

0 · Reply

PUBLIXNOOB Oct. 4 at 7:43 PM

$GIPR I’m between this , $IMG and $ICCM fir next week. Throw me some thoughts. Open to everything. I’m on a challenge to make 10k next week!

1 · Reply

VishalMathew Oct. 4 at 5:36 PM

$ICCM I think they cannot do a lot of dilution as Icecure is subjected to baby shelf rule

0 · Reply

highnihilism Oct. 4 at 3:57 PM

$ICCM Icecure Medical volume 15,112,238 | average 1,336,145 × 11.3 | price 0.96 -0.03 (-2.6%) earnings 08-13-25 bmo event 10-06-25

0 · Reply

Aimoney Oct. 4 at 3:41 PM

$ICCM Still holding, not selling

0 · Reply

neangewo Oct. 4 at 3:09 PM

$ICCM Has anyone exercised their warrants? Looks like on ETrade and Schwab you have to call, fill out the appropriate paperwork, and then wait for shares to get delivered. Putting that in my ‘To Do’ list next week!

1 · Reply

PUBLIXNOOB Oct. 4 at 12:43 PM

$ICCM 3 to 5 on Monday imo

0 · Reply

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

Oct 3, 2025, 12:19 PM EDT - 1 day ago

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Sep 30, 2025, 8:30 AM EDT - 4 days ago

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

Sep 22, 2025, 8:30 AM EDT - 12 days ago

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

Sep 18, 2025, 8:30 AM EDT - 16 days ago

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

Sep 15, 2025, 8:30 AM EDT - 19 days ago

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Sep 8, 2025, 8:30 AM EDT - 26 days ago

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

Sep 4, 2025, 8:30 AM EDT - 4 weeks ago

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

Aug 13, 2025, 1:08 PM EDT - 7 weeks ago

IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 8:30 AM EDT - 7 weeks ago

IceCure Reports Financial & Operational Results for the First Half of 2025

Aug 6, 2025, 8:30 AM EDT - 2 months ago

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

Jul 29, 2025, 9:00 AM EDT - 2 months ago

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

Jul 25, 2025, 9:00 AM EDT - 2 months ago

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

Jul 24, 2025, 9:00 AM EDT - 2 months ago

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

Jul 10, 2025, 8:00 AM EDT - 3 months ago

IceCure Announces Commencement of Rights Offering

Jul 3, 2025, 8:30 AM EDT - 3 months ago

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

Jun 25, 2025, 9:23 AM EDT - 3 months ago

IceCure Announces Record Date for Rights Offering for Up to $10 Million

Jun 9, 2025, 8:30 AM EDT - 4 months ago

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

May 28, 2025, 4:26 PM EDT - 4 months ago

IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript

May 28, 2025, 8:30 AM EDT - 4 months ago

IceCure Medical Reports First Quarter 2025 Financial Results

May 21, 2025, 8:30 AM EDT - 4 months ago

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

May 6, 2025, 8:30 AM EDT - 5 months ago

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

Apr 30, 2025, 8:30 AM EDT - 5 months ago

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

Apr 28, 2025, 8:30 AM EDT - 5 months ago

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

Apr 22, 2025, 8:30 AM EDT - 5 months ago

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

Mar 27, 2025, 1:45 PM EDT - 6 months ago

IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:30 AM EDT - 6 months ago

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

Mar 24, 2025, 8:30 AM EDT - 6 months ago

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

Mar 21, 2025, 8:30 AM EDT - 7 months ago

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

Mar 20, 2025, 8:30 AM EDT - 7 months ago

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

Mar 18, 2025, 8:30 AM EDT - 7 months ago

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

Mar 17, 2025, 8:30 AM EDT - 7 months ago

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Mar 10, 2025, 8:30 AM EDT - 7 months ago

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

Feb 24, 2025, 8:30 AM EST - 7 months ago

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

Feb 4, 2025, 8:30 AM EST - 8 months ago

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

Jan 27, 2025, 8:30 AM EST - 8 months ago

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

Jan 13, 2025, 7:00 AM EST - 9 months ago

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

Jan 6, 2025, 8:30 AM EST - 9 months ago

IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule

Jan 3, 2025, 8:30 AM EST - 9 months ago

European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology

Dec 16, 2024, 8:30 AM EST - 10 months ago

Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

Nov 26, 2024, 1:46 PM EST - 11 months ago

IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript

Nov 26, 2024, 8:30 AM EST - 11 months ago

IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation

Nov 25, 2024, 8:30 AM EST - 11 months ago

IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office

Nov 20, 2024, 8:30 AM EST - 11 months ago

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

Nov 19, 2024, 8:30 AM EST - 11 months ago

IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

Nov 8, 2024, 7:00 AM EST - 11 months ago

FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer

Oct 29, 2024, 8:30 AM EDT - 1 year ago

Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders

Oct 21, 2024, 8:30 AM EDT - 1 year ago

IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System

Oct 7, 2024, 8:15 AM EDT - 1 year ago

IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference

Sep 24, 2024, 8:15 AM EDT - 1 year ago

IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate

Seti09 Oct. 5 at 1:16 AM

$ICCM I Expect off-label to go parabolic.

1 · Reply

Seti09 Oct. 5 at 1:11 AM

1 · Reply

Seti09 Oct. 4 at 10:00 PM

$GIPR $IMG $ICCM Everything, try DVLT.

0 · Reply

DreyOfAllTrades Oct. 4 at 8:50 PM

$ICCM This could be a good buy monday. Volume and AH was looking pretty nice

0 · Reply

PUBLIXNOOB Oct. 4 at 7:43 PM

$GIPR I’m between this , $IMG and $ICCM fir next week. Throw me some thoughts. Open to everything. I’m on a challenge to make 10k next week!

1 · Reply

VishalMathew Oct. 4 at 5:36 PM

$ICCM I think they cannot do a lot of dilution as Icecure is subjected to baby shelf rule

0 · Reply

highnihilism Oct. 4 at 3:57 PM

$ICCM Icecure Medical volume 15,112,238 | average 1,336,145 × 11.3 | price 0.96 -0.03 (-2.6%) earnings 08-13-25 bmo event 10-06-25

0 · Reply

Aimoney Oct. 4 at 3:41 PM

$ICCM Still holding, not selling

0 · Reply

neangewo Oct. 4 at 3:09 PM

1 · Reply

PUBLIXNOOB Oct. 4 at 12:43 PM

$ICCM 3 to 5 on Monday imo

0 · Reply

JoeBio Oct. 4 at 12:41 PM

$ICCM Decent trading volume y-day obviously amplified by reactions to the approval and broader investor interest. I suspect the ATM may have been utilized especially given their prior low cash reserves. The surge yesterday followed by a pullback, supports short pressure and/or profit-taking. This approval is a pivotal milestone for a niche but significant market of ~46K women annually. The FDA’s decision to limit the approval likely reflects the trial’s data, Use in younger patients is plausible as Off-label with potential future trials for broader age groups. Challenges include scaling U.S. distribution, managing costs, and existing competition. The volatility, financial constraints and potential short interest highlight required patience. With strategic execution the re's potential profitability in 2026. I'm retaining a core position and will capitalize on the the inherent ups and downs of Biotech stocks by day trading often. May all your trades and investments be profitable!

0 · Reply

Seti09 Oct. 4 at 12:15 PM

$ICCM IceCure Medical (ICCM) received FDA marketing authorization for ProSense, specifically for women aged 70 and older. However, the federal Right to Try Act supersedes this age restriction, effectively broadening the eligible patient population. This expansion is expected to drive increased interest in ProSense as a front-line treatment option.

0 · Reply

JoeBio Oct. 4 at 11:40 AM

$ICCM Real life experiences are the best teachers....May all your trades and investment be profitable

0 · Reply

Ric_1M Oct. 4 at 11:27 AM

$CRML $SOPA $BTTC $ICCM $FEMY "Once you replace negative thoughts with positive ones, you'll start having positive results." Willie Nelson

0 · Reply

Tonyboner Oct. 4 at 10:57 AM

$ICCM Mass dilution coming 100 million shelf filed 9/4/25, no more magic left here, sales have dropped by big %

1 · Reply

Rachel20201 Oct. 4 at 6:02 AM

$ICCM I am so happy for this company they will save so many lives. Well done.

0 · Reply

Amb8675309 Oct. 4 at 4:50 AM

$ICCM the following countries were waiting for FDA approval so they could file their own application to their own versions of the FDA: Japan, Canada, UK, Australia, Switzerland, UAE, Saudia Arabia. The money is in the one time use disposable probes which cost $2,000. Good news for the company- stock should move up

0 · Reply

Lirik Oct. 4 at 3:29 AM

$ICCM I’ll be honest, I’ve been waiting on this news for over a year and thought we’d see a 2x minimum on news. Not In my wildest expectations did I expect a couple warrant holder to exercise and dilute the stock 20%. That happened and they exercised because I believe they think this is only going up from here.

0 · Reply

Hieuthao Oct. 4 at 3:07 AM

$ICCM Told yaaaaaaaaaa

0 · Reply

dirty_bear Oct. 4 at 2:36 AM

$ICCM this manipulation and straight up grinding a stock into to dirt is criminal

1 · Reply

Daily1515 Oct. 4 at 1:36 AM

$ICCM if it works for women over 70.A few tweaks should help the younger generations don’t you think!? No brainer here

1 · Reply

Daily1515 Oct. 4 at 1:15 AM

$BURU $ICCM UP NEXT APPROVAL TO MOON

0 · Reply

Market Cap	68.01M
Revenue (ttm)	3.29M
Net Income (ttm)	-15.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-465.65%
Debt to Equity Ratio	0.70

Volume	17,612,699
Avg Vol	2,499,092
Day's Range	N/A - N/A
Shares Out	68.70M
Stochastic %K	8%
Beta	0.31
Analysts	Strong Sell
Price Target	$2.67